Image

TSN084 Treating Patients With Advanced Malignant Tumors

Recruiting
18 years of age
Both
Phase 1

Powered by AI

Overview

TSN084 is a novel type II kinase inhibitor with demonstrated anti-tumor effects in vitro and in vivo and targets multiple tyrosine kinases, such as c-MET, FLT3, TRK and serine/threonine kinase CDK8/19. This phase 1a/1b study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of TSN084 in advanced or metastatic malignancies in China.

Description

The phase 1a part will begin with an exploration of TSN084 dose and regimen to determine the maximum tolerated dose (MTD) and/or recommended dose for further investigation (i.e., RP2D). In Phase 1b part, separate cohorts of patients with different histological diagnosis will be evaluated for the clinical activity and efficacy of TSN084 at the recommended dose.

Eligibility

Inclusion Criteria:

  • Men or women ≥18 years old.
  • The subject fully understands the requirements of the study and voluntarily signs the written informed consent.
  • Be able to comply with the medication requirements of the study and all study related procedures and evaluations; not deemed as potentially unreliable and/or uncooperative.
  • Meeting the requirements of tumor types shown below. Phase Ia Study: Histological or cytological diagnosis of locally advanced, relapsed, or metastatic malignancies, not amenable to standard therapy or for which no standard therapy is available.
        Phase Ib study: Histological or cytological diagnosis of the locally advanced, relapsed, or
        metastatic selected malignancies not amenable to standard therapy (disease progression or
        intolerance), or unable to receive standard therapy/no standard therapy is available.
        Malignancies with targeted mutations are preferred, including but not limited to MET exon
        14 skipping mutation and MET amplification.
          -  Survival expectations are ≥ 12 weeks.
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 for Phase Ia,
             while 0 to 2 for Phase Ib.
          -  Patients with adequate organ function at the time of screening.
          -  Male and female patients of childbearing potential must agree to use effective methods
             of contraception.
        Exclusion Criteria:
          -  Patients with active brain metastases, except that their central nervous system (CNS)
             tumor metastases are confined to the supratentorial or cerebellum, have been
             adequately treated (surgery or radiotherapy), have maintained radiographic stability
             for at least 4 weeks, and do not require corticosteroids to control symptoms.
          -  Other malignancies (other than non-melanoma basal cell carcinoma or squamous cell
             carcinoma of the skin, breast/cervical carcinoma in situ, superficial bladder
             carcinoma that have received radical treatment and no evidence of disease recurrence)
             within 5 years prior to initiation of TSN084 treatment;
          -  Any arterial thromboembolic event, including myocardial infarction, unstable angina
             pectoris, cerebrovascular accident, or transient ischemic attack, occurred within 6
             months prior to enrolment;
          -  Uncontrolled third space effusion requiring repeated drainage, such as pleural
             effusion, ascites, pericardial effusion, etc. (Patients who do not need drainage
             effusion or have no significant increase in effusion after 3 days of cessation of
             drainage can be included).
          -  Has active gastrointestinal disease or other disease, or other factors such as
             surgical resection that may significantly affect drug absorption, metabolism, or
             excretion.
          -  Pregnant or lactating women.
          -  Known history of allogeneic organ transplantation and allogeneic hematopoietic stem
             cell transplantation.
          -  HIV infected patients (HIV 1/2 antibody positive).
          -  Known active syphilis infection, or active tuberculosis.
          -  A history of drug abuse or drug use.

Study details

Malignant Neoplasm

NCT06386705

Tyligand Bioscience (Shanghai) Limited

18 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.